Polar Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Polar Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$8.3M	Sell	50,000 -35,000	-41%	-$4.79M	0.06%	189
2020 Q2	$9.7M	Sell	85,000 -15,000	-15%	-$1.45M	0.08%	176
2020 Q1	$7.69M	Sell	100,000 -25,000	-20%	-$2.24M	0.08%	184
2019 Q4	$16.1M	Sell	125,000 -20,148	-14%	-$1.94M	0.14%	173
2019 Q3	$11.3M	Buy	145,148 +120,148	+481%	+$11.3M	0.1%	188
2019 Q2	$2.58M	Buy	+25,000	New	+$1.95M	0.02%	249

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Polar Capital's MRTX Position: Q3 2020 in Review

Polar Capital reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 41% in Q3 2020, selling an estimated $4.79M and leaving 50,000 shares worth $8.3M. The position accounts for 0.06% of the portfolio, ranked #189.

Polar Capital first reported a position in MRTX in Q2 2019 and has held it in 6 quarters since. The position peaked at $16.1M in Q4 2019. 225 funds tracked by Wall St. Rank hold MRTX as of Q3 2020.

Polar Capital held 50,000 shares of Mirati Therapeutics, Inc. Common Stock worth $8.3M as of Q3 2020.
Polar Capital sold 35,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $4.79M.
Mirati Therapeutics, Inc. Common Stock made up 0.06% of Polar Capital's portfolio in Q3 2020, its #189 holding.
Polar Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 6 quarters since.
Polar Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $16.1M in Q4 2019.
225 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.